clonidine has been researched along with Alzheimer Disease in 72 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The neurobiology of aggression in Alzheimer's Disease (AD) remains unknown." | 6.71 | Growth hormone response to clonidine predicts aggression in Alzheimer's disease. ( Eryavec, G; Herrmann, N; Khan, LR; Lanctôt, KL; Van Reekum, R, 2004) |
| " The hypothesis of this study was that central NE responsivity would predict aggression response to treatment with a NE medication, pindolol." | 5.11 | Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. ( Eryavec, G; Herrmann, N; Khan, LR; Lanctôt, KL, 2004) |
| "The neurobiology of aggression in Alzheimer's Disease (AD) remains unknown." | 2.71 | Growth hormone response to clonidine predicts aggression in Alzheimer's disease. ( Eryavec, G; Herrmann, N; Khan, LR; Lanctôt, KL; Van Reekum, R, 2004) |
| "The effects of Alzheimer's disease (AD) and normal aging on resting CNS adrenergic activity were estimated by measuring cerebrospinal fluid (CSF) epinephrine (EPI) concentrations in 74 persons with AD, 42 cognitively normal healthy older persons, and 54 healthy young persons." | 2.69 | Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging. ( Brodkin, K; Dobie, DJ; Elrod, R; Jensen, C; Murray, S; Pascualy, M; Peskind, ER; Petrie, E; Raskind, MA; Veith, RC, 1998) |
| " However, pharmacological agents that enhance central cholinergic and noradrenergic neurotransmission, like physostigmine and clonidine, might have serious adverse effects." | 2.66 | Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. ( Bierer, LM; Davidson, M; Davis, KL; Kaminsky, R; Ryan, TM, 1989) |
| "Considering the complex etiology of Alzheimer's disease (AD), multifunctional agents may be beneficial for the treatment of this disease." | 1.46 | DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy. ( Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y, 2017) |
| "Patients suffering from Alzheimer's disease (AD) may show increased sensitivity to tropicamide, a muscarinic cholinoceptor antagonist." | 1.33 | Why patients with Alzheimer's disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus. ( Bradshaw, CM; Hou, RH; Langley, RW; Raisi, M; Samuels, ER; Szabadi, E, 2006) |
| "These two groups of Alzheimer's disease patients performed equally in measures of attention after placebo or clonidine administration." | 1.30 | Clonidine impairs sustained attention and memory in Alzheimer's disease. ( Jäkälä, P; Laakso, MP; Riekkinen, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (6.94) | 18.7374 |
| 1990's | 8 (11.11) | 18.2507 |
| 2000's | 7 (9.72) | 29.6817 |
| 2010's | 45 (62.50) | 24.3611 |
| 2020's | 7 (9.72) | 2.80 |
| Authors | Studies |
|---|---|
| Klein, JT | 1 |
| Davis, L | 1 |
| Olsen, GE | 1 |
| Wong, GS | 1 |
| Huger, FP | 1 |
| Smith, CP | 1 |
| Petko, WW | 1 |
| Cornfeldt, M | 1 |
| Wilker, JC | 1 |
| Blitzer, RD | 1 |
| Landau, E | 1 |
| Haroutunian, V | 2 |
| Martin, LL | 1 |
| Effland, RC | 1 |
| Marco-Contelles, J | 1 |
| León, R | 3 |
| de los Ríos, C | 1 |
| Samadi, A | 1 |
| Bartolini, M | 3 |
| Andrisano, V | 3 |
| Huertas, O | 2 |
| Barril, X | 1 |
| Luque, FJ | 3 |
| Rodríguez-Franco, MI | 5 |
| López, B | 3 |
| López, MG | 4 |
| García, AG | 3 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 4 |
| Camps, P | 1 |
| Formosa, X | 1 |
| Galdeano, C | 1 |
| Muñoz-Torrero, D | 3 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 2 |
| Badia, A | 1 |
| Clos, MV | 2 |
| Mancini, F | 1 |
| Arce, MP | 4 |
| Dafni, T | 1 |
| González-Muñoz, GC | 2 |
| Pérez, C | 3 |
| Conde, S | 3 |
| Romero, A | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Egea, J | 2 |
| Tang, H | 3 |
| Zhao, LZ | 1 |
| Zhao, HT | 2 |
| Huang, SL | 2 |
| Zhong, SM | 2 |
| Qin, JK | 1 |
| Chen, ZF | 2 |
| Huang, ZS | 2 |
| Liang, H | 2 |
| Wang, ZY | 1 |
| Sun, Y | 2 |
| Chen, J | 1 |
| Chen, X | 1 |
| Huang, L | 3 |
| Li, X | 5 |
| Di Pietro, O | 1 |
| Pérez-Areales, FJ | 2 |
| Juárez-Jiménez, J | 1 |
| Espargaró, A | 2 |
| Pérez, B | 3 |
| Sabaté, R | 2 |
| Miao, H | 1 |
| Meng, F | 1 |
| Lan, JS | 4 |
| Xie, SS | 5 |
| Li, SY | 1 |
| Pan, LF | 1 |
| Wang, XB | 9 |
| Kong, LY | 11 |
| Sang, Z | 12 |
| Li, Y | 11 |
| Qiang, X | 10 |
| Xiao, G | 7 |
| Liu, Q | 2 |
| Tan, Z | 12 |
| Deng, Y | 11 |
| Jiang, N | 4 |
| Dong, G | 1 |
| Li, ZR | 2 |
| Wang, KD | 2 |
| Guo, PP | 1 |
| Wang, X | 3 |
| Yu, W | 1 |
| Wang, ZM | 3 |
| Li, F | 5 |
| Wu, JJ | 6 |
| Wang, J | 5 |
| Pan, W | 3 |
| Hu, K | 1 |
| Bai, P | 3 |
| Yu, L | 5 |
| Ma, Q | 5 |
| Li, T | 1 |
| Zhang, X | 3 |
| Chen, C | 1 |
| Peng, K | 1 |
| Liu, W | 13 |
| Luo, L | 6 |
| Li, XM | 1 |
| Cai, P | 6 |
| Liu, QH | 5 |
| Xu, DQ | 1 |
| Yang, XL | 6 |
| Wei, S | 1 |
| Chen, W | 1 |
| Qin, J | 1 |
| Huangli, Y | 1 |
| Wang, L | 1 |
| Shen, Y | 1 |
| Yang, X | 5 |
| Zheng, Y | 4 |
| Cao, Z | 6 |
| Su, F | 2 |
| Ai, J | 1 |
| Xu, R | 5 |
| Song, Q | 5 |
| Xia, CL | 1 |
| Wang, N | 1 |
| Guo, QL | 1 |
| Liu, ZQ | 1 |
| Wu, JQ | 1 |
| Ou, TM | 1 |
| Tan, JH | 1 |
| Wang, HG | 1 |
| Li, D | 1 |
| Monjas, L | 1 |
| Gil, C | 1 |
| Wang, K | 8 |
| Yang, Y | 1 |
| Leng, C | 1 |
| Xu, Q | 1 |
| Yang, HL | 3 |
| Fang, SQ | 1 |
| Tang, YW | 2 |
| Wang, C | 2 |
| Wang, H | 6 |
| Ye, M | 2 |
| Han, X | 2 |
| Xu, YX | 1 |
| Li, XK | 1 |
| Dong, SN | 1 |
| Liu, WW | 1 |
| Gong, Q | 2 |
| Wang, TD | 1 |
| Tang, Y | 1 |
| Zhu, J | 2 |
| Li, J | 2 |
| Zhang, HY | 1 |
| Mao, F | 2 |
| Huang, Q | 1 |
| Liu, J | 1 |
| Liang, N | 1 |
| Li, Q | 3 |
| Yang, J | 2 |
| Liu, H | 4 |
| Yang, Z | 2 |
| Xu, Y | 2 |
| Zhang, J | 2 |
| Wang, W | 1 |
| Qiu, X | 1 |
| Zhang, H | 1 |
| Tian, C | 1 |
| Shi, CJ | 1 |
| Hu, J | 1 |
| Pan, T | 1 |
| An, B | 1 |
| Li, Z | 1 |
| Li, W | 1 |
| He, Y | 1 |
| Ye, C | 1 |
| Shi, J | 5 |
| Zhang, P | 3 |
| Turcu, AL | 2 |
| Barniol-Xicota, M | 1 |
| Pont, C | 1 |
| Pivetta, D | 1 |
| De Simone, A | 1 |
| Sureda, FX | 2 |
| Vázquez, S | 2 |
| Zhu, G | 1 |
| Yang, D | 1 |
| Fan, X | 1 |
| Zhang, Z | 2 |
| Cheng, X | 1 |
| Zhang, Q | 1 |
| Zheng, C | 1 |
| Cheng, Y | 1 |
| Lu, X | 1 |
| Jiang, X | 4 |
| Zhou, J | 1 |
| Wang, Y | 4 |
| Chen, L | 2 |
| Duan, Y | 1 |
| Huang, J | 1 |
| Liu, C | 2 |
| Chen, Y | 2 |
| Sun, H | 2 |
| Feng, F | 2 |
| Qu, W | 1 |
| Xing, C | 1 |
| Lyu, W | 1 |
| Wang, S | 2 |
| Chen, T | 1 |
| Qu, L | 1 |
| Ji, L | 1 |
| Luo, H | 1 |
| Li, S | 1 |
| Peng, W | 1 |
| Yin, F | 1 |
| Lu, D | 1 |
| Liu, X | 2 |
| Kong, L | 1 |
| Tian, L | 1 |
| Gao, Y | 1 |
| Chen, H | 1 |
| Xu, Z | 1 |
| Ding, H | 1 |
| Zhao, Q | 1 |
| Zuo, J | 1 |
| Wu, C | 1 |
| Zha, L | 1 |
| Liu, XH | 1 |
| Tang, W | 1 |
| Sun, X | 1 |
| Lei, Z | 1 |
| Yue, S | 1 |
| Sun, J | 1 |
| Companys-Alemany, J | 1 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 1 |
| Loza, MI | 1 |
| Brea, JM | 1 |
| Soto, D | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 1 |
| Pallàs, M | 1 |
| Herrmann, N | 2 |
| Lanctôt, KL | 2 |
| Eryavec, G | 2 |
| Van Reekum, R | 1 |
| Khan, LR | 2 |
| Hou, RH | 1 |
| Samuels, ER | 1 |
| Raisi, M | 1 |
| Langley, RW | 1 |
| Szabadi, E | 1 |
| Bradshaw, CM | 1 |
| Peskind, ER | 3 |
| Wingerson, D | 1 |
| Murray, S | 2 |
| Pascualy, M | 2 |
| Dobie, DJ | 2 |
| Le Corre, P | 1 |
| Le Verge, R | 1 |
| Veith, RC | 2 |
| Raskind, MA | 3 |
| Elrod, R | 1 |
| Petrie, E | 1 |
| Jensen, C | 1 |
| Brodkin, K | 1 |
| Riekkinen, P | 1 |
| Riekkinen, M | 2 |
| Laakso, MP | 1 |
| Jäkälä, P | 1 |
| Holmes, C | 1 |
| Goldstein, DS | 1 |
| Cedazo-Mínguez, A | 1 |
| Hamker, U | 1 |
| Meske, V | 1 |
| Veh, RW | 1 |
| Hellweg, R | 1 |
| Jacobi, C | 1 |
| Albert, F | 1 |
| Cowburn, RF | 2 |
| Ohm, TG | 1 |
| O'Neill, C | 2 |
| Fowler, CJ | 2 |
| Wiehager, B | 1 |
| Alafuzoff, I | 1 |
| Winblad, B | 2 |
| Santucci, AC | 1 |
| Davis, KL | 2 |
| Mohr, E | 1 |
| Schlegel, J | 1 |
| Fabbrini, G | 1 |
| Williams, J | 1 |
| Mouradian, MM | 1 |
| Mann, UM | 1 |
| Claus, JJ | 1 |
| Fedio, P | 1 |
| Chase, TN | 1 |
| Davidson, M | 1 |
| Bierer, LM | 1 |
| Kaminsky, R | 1 |
| Ryan, TM | 1 |
| Gilles, C | 1 |
| Ryckaert, P | 1 |
| De Mol, J | 1 |
| de Maertelaere, V | 1 |
| Mendlewicz, J | 1 |
| Davous, P | 1 |
| Roudier, M | 1 |
| Piketty, ML | 1 |
| Abramowitz, C | 1 |
| Lamour, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)[NCT03710642] | Phase 2 | 35 participants (Actual) | Interventional | 2018-10-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The ADCS-ADL-Severe questionnaire is a secondary outcome measure aimed at detecting functional decline in people with severe AD. This scale is best suited for evaluating people with MMSE scores below 15/30, or equivalent. Questions are administered to a qualified caregiver informant about a set of 19 basic and instrumental ADL. Instrumental ADL are selected to be relevant to this level of severity of dementia, e.g., obtaining a beverage, turning lights on and off, turning a faucet on and off. Performance of each of these activities during the past 4 weeks, as well as the level of performance, are rated. A total score is derived by summing scores across items, and ranges from 0 (maximal impairment) to 54 (maximally independent function).~This outcome is the change from baseline to week 12." (NCT03710642)
Timeframe: 12 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | -1.47055 |
| Placebo Oral Capsule | -4.53993 |
"The ADCS-CGIC-A is the primary outcome measure. It will be anchored to disruptive agitation, the target behaviors in this study. It measures whether the effects of active treatment are substantial enough to be detected by a skilled and experienced clinician on the basis of a direct examination of the participant and an interview of the participant's primary caregiver and other LTC facility staff. The baseline assessment is qualitative therefore there is no score at baseline; post-baseline scores represent a change score compared to baseline.~The ADCS-CGIC-A is a 7-point scale that is structured as the clinician's assessment of change from baseline compared to the ADCS-CGIC-A Baseline Worksheet. There is no baseline score; post-baseline scores range from 1 (improvement) to 7 (worsening). A score of 1-2 indicates clinically meaningful improvement; a score of 3-5 indicates no clinically meaningful change; a score of 6-7 indicates clinically meaningful worsening." (NCT03710642)
Timeframe: From Baseline through Week 12.
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | 3.434 |
| Placebo Oral Capsule | 3.442 |
"Comparison of effects on caregiver distress/occupational disruptiveness scores on the NPI/NPI-NH. Minimum score is 0 and maximum score is 60. A higher score is a worse outcome.~This outcome is the change from baseline to week 12." (NCT03710642)
Timeframe: 12 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | -2.4438 |
| Placebo Oral Capsule | 0.9446 |
"The NPI was designed to characterize the neuropsychiatric symptoms and psychopathology of patients with AD and other dementias residing in the community about which information was obtained from family caregivers. The content of the questions and their scoring in the NPI-NH are identical to those of the NPI except for some slight rephrasing to be consistent with the LTC environment where information is gathered from professional caregivers. Assessment of the impact of behavioral disturbances on family and professional caregivers, is assessed by a caregiver distress scale in the NPI and an occupational disruptiveness scale in the NPI-NH; scoring of this component remains identical. Minimum score is 0 and highest score is 144. A higher score means a worse outcome.~This outcome is the change from baseline to week 12." (NCT03710642)
Timeframe: 12 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Treatment (Prazosin) | -6.033 |
| Placebo Oral Capsule | 5.506 |
Cumulative total dose of Lorazepam rescue medication administered during the trial. Information on the total mg rescue lorazepam administered will be collected as additional secondary outcome measures. If prazosin is more effective than placebo, it is predicted that participants randomized to prazosin will be prescribed lower cumulative mg of rescue lorazepam for management of persistent or worsening disruptive agitation. (NCT03710642)
Timeframe: 12 weeks
| Intervention | mg (Mean) |
|---|---|
| Treatment (Prazosin) | 0.25 |
| Placebo Oral Capsule | 0.14 |
Comparison of proportions of responders versus non responders on the ADCS-CGIC-A. Responders are defined as those with moderate or marked improvement in agitation symptoms compared to baseline assessment. (NCT03710642)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Prazosin) | 7 |
| Placebo Oral Capsule | 1 |
Cox proportional hazard modelling comparing the median time to drop out between treatment groups. (NCT03710642)
Timeframe: 12 weeks
| Intervention | days (Median) |
|---|---|
| Treatment (Prazosin) | 65.63 |
| Placebo Oral Capsule | 54.62 |
7 trials available for clonidine and Alzheimer Disease
| Article | Year |
|---|---|
Growth hormone response to clonidine predicts aggression in Alzheimer's disease.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Behavioral Sympto | 2004 |
Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Behavioral Symptoms; C | 2004 |
Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine.
Topics: Adult; Aged; Aging; Alzheimer Disease; Ambulatory Care; Analysis of Variance; Blood Pressure; Clonid | 1995 |
Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adult; Aged; Aging; Alzheimer Disease; Bloo | 1998 |
THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease.
Topics: Adrenergic alpha-Agonists; Aged; Alzheimer Disease; Blood Pressure; Clonidine; Double-Blind Method; | 1999 |
Clonidine treatment of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Blood Pressure; Clinical Trials as Topic; Clonidine; Female; Humans; Hypnot | 1989 |
Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.
Topics: Aged; Alzheimer Disease; Blood Pressure; Clinical Trials as Topic; Clonidine; Female; Heart Rate; Hu | 1989 |
65 other studies available for clonidine and Alzheimer Disease
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biogenic Amines; Brain; In Vitro Techniques; Indoles; Magnetic Resonance | 1996 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly | 2009 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood- | 2011 |
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Bra | 2012 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro | 2013 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response | 2014 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B | 2014 |
Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain B | 2014 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyr | 2015 |
Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties.
Topics: Alzheimer Disease; Animals; Antioxidants; Biphenyl Compounds; Blood-Brain Barrier; Cell Survival; Ch | 2015 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel | 2015 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Chol | 2016 |
Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alkanes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Chemi | 2016 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; C | 2016 |
Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain B | 2016 |
Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell S | 2016 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesteras | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; D | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inh | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Bloo | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors | 2017 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholine | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2017 |
Synthesis and pharmacological evaluation of novel chromone derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Binding Sites; Blood-Bra | 2017 |
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relations | 2017 |
Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzylamines; Blood-Retinal Barrier; | 2017 |
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Dose-Response Relationship, Drug; | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chol | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood- | 2017 |
Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; | 2018 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell L | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Br | 2018 |
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2018 |
Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Dimerization; Humans; Mice | 2019 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester | 2019 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cho | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyry | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase I | 2019 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitor | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Developm | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Tr | 2019 |
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inh | 2020 |
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug | 2021 |
Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Antioxidants; Aspart | 2021 |
Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Dyr | 2021 |
Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholine | 2021 |
Development of 5-hydroxyl-1-azabenzanthrone derivatives as dual binding site and selective acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Binding Sites | 2022 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Why patients with Alzheimer's disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus.
Topics: Adrenergic alpha-Agonists; Adult; Alzheimer Disease; Clonidine; Cross-Over Studies; Double-Blind Met | 2006 |
Clonidine impairs sustained attention and memory in Alzheimer's disease.
Topics: Adrenergic alpha-Agonists; Aged; Alzheimer Disease; Attention; Blood Pressure; Choice Behavior; Clon | 1999 |
Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Aged; Aging; Alzheimer Disease; Antimetabol | 1999 |
Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures.
Topics: Alzheimer Disease; Animals; Animals, Newborn; Apolipoproteins E; Astrocytes; Bucladesine; Carbachol; | 2001 |
Coupling of human brain cerebral cortical alpha 2-adrenoceptors to GTP-binding proteins in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Chlorides; Clonidine; Female; GTP-Binding Proteins; Guanin | 1991 |
Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Benzylamines; Cholinergic Agents; Cholinergic Fibers | 1991 |
Alpha 1-adrenergic receptor binding sites in post-mortal human cerebral microvessel preparations: preservation in multi-infarct dementia and dementia of Alzheimer type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cerebrovascular Circulation; Clonidine; | 1989 |
Clonidine-induced growth hormone secretion in elderly patients with senile dementia of the Alzheimer type and major depressive disorder.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Clonidine; Depressive Disorder; Diagnosis, Differential; | 1989 |
Pharmacological modulation of cortisol secretion and dexamethasone suppression in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Clonidine; Depressive Disorder; Dexamethasone; Female; H | 1988 |